Imatinib inhibits vascular smooth muscle proteoglycan synthesis and reduces LDL binding in vitro and aortic lipid deposition in vivo

Ballinger, M, Osman, N, Hashimura, K, de Haan, J, Jandeleit-Dahm, K, Allen, T, Tannock, L, Rutledge, J and Little, P 2009, 'Imatinib inhibits vascular smooth muscle proteoglycan synthesis and reduces LDL binding in vitro and aortic lipid deposition in vivo', Journal of Cellular and Molecular Medicine, vol. 14, no. 6B, pp. 1408-1418.


Document type: Journal Article
Collection: Journal Articles

Title Imatinib inhibits vascular smooth muscle proteoglycan synthesis and reduces LDL binding in vitro and aortic lipid deposition in vivo
Author(s) Ballinger, M
Osman, N
Hashimura, K
de Haan, J
Jandeleit-Dahm, K
Allen, T
Tannock, L
Rutledge, J
Little, P
Year 2009
Journal name Journal of Cellular and Molecular Medicine
Volume number 14
Issue number 6B
Start page 1408
End page 1418
Total pages 11
Publisher Wiley-Blackwell Publishing Ltd.
Abstract The 'response to retention' hypothesis of atherogenesis proposes that proteoglycans bind and retain low-density lipoproteins (LDL) in the vessel wall. Platelet-derived growth factor (PDGF) is strongly implicated in atherosclerosis and stimulates proteoglycan synthesis. Here we investigated the action of the PDGF receptor inhibitor imatinib on PDGF-mediated proteoglycan biosynthesis in vitro, lipid deposition in the aortic wall in vivo and the carotid artery ex vivo. In human vSMCs, imatinib inhibited PDGF mediated 35S-SO4 incorporation into proteoglycans by 31% (P < 0.01) and inhibited PDGF-mediated size increases in both chemically cleaved and xyloside associated glycosaminoglycan (GAG) chains by 19%, P < 0.05 and 27%, P < 0.05, respectively. Imatinib decreased PDGF stimulation of the 6:4 position sulphation ratio of disaccharides. The half maximal saturation value for LDL binding for proteoglycans from PDGF stimulated cells in the presence of imatinib was approximately 2.5-fold higher than for PDGF treatment alone. In high fat fed ApoE-/- mice, imatinib reduced total lipid staining area by ~31% (P < 0.05). Carotid artery lipid accumulation in imatinib treated mice was also reduced. Furthermore, we demonstrate that imatinib inhibits phosphorylation of tyrosine 857, the autophosphorylation site of the PDGF receptor, in vSMCs. Thus imatinib inhibits GAG synthesis on vascular proteoglycans and reduces LDL binding in vitro and in vivo and this effect is mediated via the PDGF receptor. These findings validate a novel mechanism to prevent cardiac disease.
Keyword(s) Atherosclerosis
Glycosaminoglycans
Protein tyrosine kinase
Proteoglycans
Vascular smooth muscle
DOI - identifier 10.1111/j.1582-4934.2009.00902.x
Copyright notice © 2009 The Authors Journal compilation © 2010 Foundation for Cellular and Molecular Medicine/Blackwell Publishing Ltd
ISSN 1582-1838
Versions
Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 36 times in Thomson Reuters Web of Science Article | Citations
Scopus Citation Count Cited 30 times in Scopus Article | Citations
Altmetric details:
Access Statistics: 92 Abstract Views  -  Detailed Statistics
Created: Fri, 07 Jan 2011, 09:11:00 EST by Catalyst Administrator
© 2014 RMIT Research Repository • Powered by Fez SoftwareContact us